Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia
Go back to Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia| (NASDAQ: KURA) | Delayed: 9.96 -0.02 (0.2%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.98 | 52 Week High | $8.90 | |||
| Open | $10.04 | 52 Week Low | $2.50 | |||
| Day High | $10.18 | P/E | N/A | |||
| Day Low | $9.93 | EPS | $0.00 | |||
| Volume | 386,391 | |||||



